Pralmorelin (INN) (trade name GHRP Kaken 100; Former development code names KP-102, GPA-748, WAY-GPA-748), also known as pralmorelin hydrochloride (JAN) and pralmorelin dihydrochloride (USAN), and in particular, Growth hormone releasing Peptide 2 (GHRP-2), a growth hormone secretagotor (GHS), is used as a diagnostic agent and marketed in single-dose formulation form by Kaken Pharmaceutical of Japan for the assessment of growth hormone deficiency (GHD). Pralmorelin is a synthetic peptide drug with oral activity. Specifically, it is an analogue of methoxyenkephalin with amino acid sequence D-Ala-D -(β-naphthyl) -ala-trp-d-phe -Lys-NH 2. It acts as an auxin releasing peptide/growth hormone secretin receptor (GHSR) agonist and is the first drug of its kind to be introduced into the clinic. Acute administration of the drug significantly increases plasma growth hormone (GH) levels and reliably induces hunger and increases food intake in humans. Pralmorelin is also being studied for GHD and short stature (pituitary dwarfism) and entered phase II clinical trials for these indications, but ultimately never made it to market. This may be because pramoline's ability to increase plasma GH levels is significantly lower in GHD patients than in healthy individuals